International Conference on Harmonisation; Draft Guidance on M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals; Availability

Document ID: FDA-2008-D-0470-0001

Comments

Total: 9

Novo Nordisk Inc. - Comment
Posted : 10/15/2008 ID ：FDA-2008-D-0470-0003 Agency : FDA

Comment Period Closed
Oct 20,2008 11:59 PM ET

Eli Lilly and Company - Comment
Posted : 10/16/2008 ID ：FDA-2008-D-0470-0004 Agency : FDA

Comment Period Closed
Oct 20,2008 11:59 PM ET

Sanofi-aventis - Comment
Posted : 10/17/2008 ID ：FDA-2008-D-0470-0005 Agency : FDA

Comment Period Closed
Oct 20,2008 11:59 PM ET

Bristol-Myers Squibb Company - Comment
Posted : 10/17/2008 ID ：FDA-2008-D-0470-0006 Agency : FDA

Comment Period Closed
Oct 20,2008 11:59 PM ET

AstraZeneca - Comment
Posted : 10/20/2008 ID ：FDA-2008-D-0470-0007 Agency : FDA

Comment Period Closed
Oct 20,2008 11:59 PM ET

ICAPPP - Comment
Posted : 10/20/2008 ID ：FDA-2008-D-0470-0008 Agency : FDA

Comment Period Closed
Oct 20,2008 11:59 PM ET

Merck & Co., Inc. - Comment
Posted : 10/20/2008 ID ：FDA-2008-D-0470-0009 Agency : FDA

Comment Period Closed
Oct 20,2008 11:59 PM ET

Biogen Idec - Comment
Posted : 10/20/2008 ID ：FDA-2008-D-0470-0010 Agency : FDA

Comment Period Closed
Oct 20,2008 11:59 PM ET

Gilead Sciences, Inc. - Comment
Posted : 10/22/2008 ID ：FDA-2008-D-0470-0011 Agency : FDA

Comment Period Closed
Oct 20,2008 11:59 PM ET